

Faculty Presenters

John Colombo, PhD

Professor of Psychology
Director of the Schiefelbusch
Institute for Life Span Studies
University of Kansas
Lawrence, Kansas

Sean Deoni, PhD

Associate Professor of Pediatrics and Radiology Director, Advanced Baby Imaging Lab Warren Alpert Medical School Brown University Pawtucket, Rhode Island Rafael Jimenez-Flores, PhD

Professor

J.T. Parker Endowed Chair in

Dairy Foods

College of Food, Agricultural, and

Environmental Sciences

Department of Food Science and

Technology

The Ohio State University

Columbus, Ohio

Faculty Disclosures

It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in accredited programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others whose products or services are discussed.

John Colombo, PhD

Advisory Board	Ingenuity Foods, LLC and Nestle
Consultant	Reckitt Mead Johnson Nutrition

Research Support Fonterra Bands, Inc.

Sean Deoni, PhD

Speakers Bureau Mead Johnson Nutrition, Nestle Nutrition, Wyeth Nutrition

Rafael Jimenez-Flores, PhD

No relationships to disclose.

Faculty have documented that this presentation will involve discussion of unapproved or off-label, experimental, or investigational use. For complete disclosure information, please see our course syllabus.

Learning Objectives

By participating in this education, you will better:



Describe the molecular structure of MFGM as it relates to its key biological functions, including its role as a bioactive component in human milk



Identify the clinical significance of MFGM in early life nutrition and its impact on neurodevelopment and brain structure and function



Discuss the longitudinal benefits of early life MFGM supplementation on cognitive outcomes, measures of intelligence, and executive functioning

The Early Nutrition Journey and MFGM: Evidence for Improving Cognitive Outcomes


- The Science and Structure of MFGM and Mechanisms of Action of MFGM on Health
- 2 MFGM and the Developing Brain

Supplemental MFGM and Neurodevelopmental Outcomes

The Science & Structure of MFGM

Rafael Jimenez-Flores, PhD

Link Between MFGM and Human Health



MFGM Benefits: Results From Selected International Studies

Study (Year)	Country	Neurodevelopment	Immune System	Other
Zavaleta et al (2011)	Peru		Less bloody diarrhea at 12 months	
Gurnida et al (2012)	Indonesia	Better coordination and performance at 6 months		
Veereman-Wauters et al (2012)	Belgium, France, Netherlands	Better behavior in preschoolers	Fewer fever episodes at 6 weeks	
Tanaka et al (2013)	Japan	Better behavior and attention in premature infants at 18 months		
Timby et al (2014)	Sweden	Better cognitive development scores at 12 months		
Timby N et al (2015)	Sweden		Lower incidence of otitis media at 6 months	
Li et al (2019)	China	Better cognitive, language, and motor functions at 12 months	Less diarrhea and IVRA	
Jaramillo-Ospina et al (2022)	Chile			Growth and safety

MFGM & Cognitive Development: Short- & Long-Term Outcomes in the Lighthouse Clinical Trial

THE JOURNAL OF PEDIATRICS • www.jpeds.com

ORIGINAL ARTICLES

Improved Neurodevelopmental Outcomes Associated with Bovine Milk Fat Globule Membrane and Lactoferrin in Infant Formula: A Randomized, Controlled Trial

Fei Li, MD, PhD¹, Steven S. Wu, MD², Carol Lynn Berseth, MD^{2,3}, Cheryl L. Harris, MS², James D. Richards, PhD^{4,5}, Jennifer L. Wampler, PhD², Weihong Zhuang, MS², Geoffrey Cleghorn, MD^{2,6}, Colin D. Rudolph, MD, PhD^{2,7}, Bryan Liu, MD, PhD^{2,8}, D. Jill Shaddy, MA⁹, and John Colombo, PhD⁹

Accelerated neurodevelopmental profile at 1 year following MFGM/lactoferrin supplementation (Li F et al, *J Pediatr*, 2019)

THE JOURNAL OF PEDIATRICS • www.jpeds.com

ORIGINAL ARTICLES



Improved Neurodevelopmental Outcomes at 5.5 Years of Age in Children Who Received Bovine Milk Fat Globule Membrane and Lactoferrin in Infant Formula Through 12 Months: A Randomized Controlled Trial


John Colombo, PhD¹, Cheryl L. Harris, MS², Jennifer L. Wampler, PhD², Weihong Zhuang, MS², D. Jill Shaddy, MA³, Bryan Y. Liu, MD, PhD⁴, and Steven S. Wu, MD^{2,5}

Improved cognitive outcomes in multiple domains at 5.5 years following MFGM/lactoferrin supplementation (Colombo J et al, *J Pediatr*, 2023)

The Science & Structure of MFGM

What Is MFGM?

The Secretion of Milk Fat




Originate as droplets within mammary epithelial cells in the mammary alveoli




Enveloped by a lipid bilayer from the plasma membrane during extrusion from the cells




Results in a complex structure enveloped by lipid trilayer containing bioactive lipids, proteins, and carbohydrates





MFGM Components



Gangliosides^{1,2}

Examples: Glycosphingolipids containing sialic acid

Role: Involved in myelination and

synaptic transmission

Sphingolipids^{1,4}

Example: Sphingomyelin

Role: Supports myelination of nerves

Proteins^{1,5,6}

Examples: mucin-1 (MUC1), lactadherin

Roles: Supports the immune system,

antimicrobial effects

Phospholipids^{1,3}

Example: Phosphatidylcholine

Role: Important component of cell membranes

TG, triglycerides



Nutrients Needed for Brain Development





Image used under a Creative Commons license (<u>CC BY</u>). © Cormack BE et al. *Nutrients*. 2019;11(9):2019.



MFGM as a Source of Nutrients for Neurodevelopment



Left image used under a Creative Commons license (CC BY). ©Podbielska M et al. Brain Sci. 2013;3(3):1282-1324.




The Science & Structure of MFGM


MFGM Production & Manufacturing

Effects of Processing on MFGM

MFGM From Raw Cream

MFGM From Pasteurized Cream






With homogenization and pasteurization, fewer large fat globules, higher amounts of proteins (blue)

Differences Between Lipids in Human Milk and Standard Infant Formula

Confocal Microscopy Images of Fat Droplets Showing Lipids (Red) and Proteins (Green)¹


Human milk



Characteristics of Human Milk Fat Droplets²

- High sphingomyelin content
- Dynamic across lactation stages
- Large fat globules (~5 µm)
- Phospholipid bilayer membrane

Standard infant formula




Characteristics of Standard Infant Formula Fat Droplets²

- High phospholipid content
- High phosphatidylcholine content
- Small fat globules (~0.2 μm)
- No phospholipid bilayer membrane


Mechanisms of Action of MFGM on Health

The Gut Microbiome

Maternal & Environmental Factors, MFGM Composition, & Effects on the Infant Gut



Bifidobacteria Populations Decline With Age




- Predominant genus in the gut microbiome of healthy breastfed infants
- May be beneficial for health across age ranges


How can we promote Bifidobacteria persistence?


Image used under a Creative Commons license (CC BY). ©Arboleya S et al. Front Microbiol. 2016;7:1204.

Milk Phospholipid Protection of *Bifidobacterium* longum ssp infantis During In Vitro Digestion



Decreased surface charge of B infantis with milk phospholipids






Thicker outer surface layer due to increase in bound polysaccharides in the presence of milk phospholipids

MPL, milk phospholipid Images used under a Creative Commons license (CC BY). ©Kosmerl E et al. Front Nutr. 2023;10:1194945.




MFGM Modifies LAB Surface and Adhesive Properties Properties

LGG in the GI Tract Without MFGM¹




Bacterial adhesion to Caco-2 TC7 intestinal cells

LGG in the GI Tract With MFGM¹



Inhibition of bacterial adhesion to Caco-2 TC7 intestinal cells

Differential Adhesion Behavior After Treatment With MFGM²




Strain-dependent effects of milk phospholipids on bacterial surface properties and subsequent adhesion


LAB, lactic acid-producing bacteria; LGG, Lactobacillus rhamnosus GG; QCM-D, quartz crystal microbalance with dissipation monitoring.




MFGM Phospholipids and the Intestinal Epithelial Barrier

Caco-2 Cells After Incubation With Labelled MFGM








Evidence of fusion between the intestinal cell plasma membrane and the phospholipids in MFGM


After incubation with MFGM, Caco-2 cells had significant changes in lipid composition:


- ↑ Triacylglycerols (TAG)
- ↑ Phosphatidylcholine
- ↓ Cholesterol esters

Images used under a Creative Commons license (CC BY). ©Martínez-Sánchez V et al. Food Res Int. 2023;173(Pt 1):113330.


MFGM Facilitates Maintenance of the Intestinal Barrier Integrity







In DSS-exposed cells,
MFGM exposure
maintains intact
mucosal barrier and
brush border with mucin
production (blue arrow)



DSS, dextran sodium sulfate Images used under a Creative Commons license (<u>CC BY</u>). © Kosmerl E et al. *Nutrients*. 2024;16(7):954.

Mechanisms of Action of MFGM on Health

The Gut-Brain Axis

The Gut-Brain Axis: Mediating the Effects of MFGM






Image used under a Creative Commons license (<u>CC BY</u>). ©Yuan C et al. *Front Cell Infect Microbiol*. 2023;13:1282431.




MFGM Components Support Nerve Myelination and Synaptic Transmission



Dairy Phospholipids Support Cortical Neuron Growth & Stimulation




Untreated neurons
Negative control




FCS-treated neurons
Positive control

Increasing phospholid extract concentration



Cortical neuron outgrowth increases after incubation with phospholipid extract


FCS, fetal calf serum



Key Takeaways

- MFGM is a complex structure enveloped by a lipid trilayer containing bioactive lipids, proteins, and carbohydrates
- MFGM has an important role in the health outcomes of the developing infant
- MFGM and its lipid constituents:
 - Fortify the mucosal barrier to protect against intestinal barrier disruption through mucin regulation
 - Facilitate healthy gut microbiota
 - Play a role in the gut-brain axis, likely via the intestinal neuronal system

Gracias!







MFGM & the Developing Brain


Early Brain Development

Sean Deoni, PhD



Early Cognitive and Behavioral Development

Age (Years)






Early Brain Development





Measures of Neurodevelopment With Age



Myelination in the Developing Brain










Myelin protects
the axon, speeds
information
transfer, and
facilitates brain
connectivity &
function

Myelination in the Developing Brain










Simplistic behaviors and primary cognitive abilities



Complex behaviors and coordinated cognitive skills

MFGM & the Developing Brain

Nutrition, Human Milk, & Neurodevelopment

Nutritional Needs for the Developing Brain


Lipids & Fatty Acids	Minerals	Vitamins	Micronutrients
 LC-PUFAs (eg, DHA, ARA) Promote healthy neural growth and development Regulate membrane function Involved in lipid biosynthesis and myelination ~20% of the fatty acid content of the brain Phospholipids (eg, phosphatidylcholine) ~10% of the lipid weight of myelin Sphingolipids (eg, sphingomyelin) Critical components of the myelin sheath Cholesterol Essential constituent of myelin Necessary for myelin membrane synthesis 	 Utilized by oligodendrocytes (myelin-producing cells) Zinc Helps bind myelin basic proteins to the myelin membrane 	 Helps convert L- methylmalonyl coenzyme A into succinylcholine coenzyme A Required for synthesis of myelin phospholipids Vitamin K Can increase sulfatides, which are incorporated into the myelin sheath to maintain structure and function 	• Promotes oligodendrocyte s and their precursors, influencing myelination and remyelination


Breastmilk provides all of these nutrients – with the exception of iron – at the right time and in the ideal amount.



Breastfeeding & Child Neurodevelopment


Studies consistently show improved cognitive development and academic outcomes in individuals who were breastfed as infants; enhanced as a function of breastfeeding duration.






Potential Underlying Biological Mechanism

Human Milk Nutrients




Brain Development



Cognitive Development



Nutrition & Early Neurodevelopment



Duration of breastfeeding associated with:

- Cortical thickness in the superior and inferior parietal lobes
- Performance IQ

Percentage of breast milk in diet associated with:2

- Verbal IQ
- White matter volume

Relative to formula-fed infants, breastfed infants had:3

- Higher IQ scores
- Larger total gray matter, and subcortical gray matter volumes




The Challenges of Pediatric MRI



Breastfeeding & Neurodevelopment (Cross-Sectional Study)


of toddlers (6-60 months of age) who were exclusively breastfed (n = 62) or formula fed (n = 38) for at least 3 months.



	Exclusively breastfed	Exclusively formula fed	<i>P</i> value
Fine motor	64.8 ± 10.9	56 ± 7.7	<.0001
Visual reception	56.2 ± 8.7	51.3 ± 10.8	.0085
Receptive language	61.9 ± 7.7	49.3 ± 12.5	<.0001
Expressive language	50.5 ± 13	43.3 ± 13.3	.0063

Breastfeeding & Neurodevelopment (Longitudinal Study)


of toddlers (2-76 months of age) who were exclusively breastfed (n = 62) or formula fed (n = 88) for at least 3 months.





Influence of Nutrition Intake

Nutrient	Formula 1	Formula 2	Formula 3	% Difference (Min-Max)
ARA (mg/L)	173	238	255	32
DHA (mg/L)	62.2	117	120.6	48
Folic Acid (µg/L)	304	232	146.2	52
Phosphatidylcholine (mg/L)	85	58	60	29
Sphingomyelin (mg/L)	28.1	62	28.1	55
Iron (mg/100g)	10.6	8.42	11.65	28
Choline (mg/100)	170	92.5	144	46




^{*}Significant differences in intercept and slope between **formula #1** and **breastfeeding** and other formulas;



^{*}General difference in intercept of each formula and breastfeeding in ELC scores


Nutrition Differentially Impacts Regional Growth

Region	ARA	DHA	Folic acid	Phosphatidyl- choline	Sphingo- myelin	Iron	Choline
Frontal WM	.002	.002	.030	<.0001	<.0001	.150	.004
Temporal WM	.040	.030	.170	.004	.002	.340	.260
Parietal WM	<.0001	<.0001	.005	<.0001	<.0001	.080	.080
Occipital WM	<.0001	<.0001	<.0001	<.0001	<.0001	<.0001	.006
Cerebellar WM	<.0001	<.0001	.013	<.0001	<.0001	<.0001	.020
Corpus callosum (body)	.003	.020	.450	<.0001	<.0001	.280	.076
Corpus callosum (genu)	.090	.150	.630	<.0001	<.0001	.270	.430
Corpus callosum (splenium)	.050	.020	.760	<.0001	<.0001	.560	.860




Nutrition Differentially Impacts Regional Growth

Myelin Sheath phospholipid cholesterol Mog Myelin sheath



Testing the Role of Sphingomyelin and Other Nutrients in Neurodevelopment

Design of a Nutritional RCT Investigating Sphingomyelin Intake and Myelination




Nutrients	Investigational Formula	Control Formula	Human Milk Reference ^a				
Energy, kcal/200 mL	132	132					
	Myelin blend						
Sphingomyelin (mg/L)	105	22	86.7				
DHA (mg/L)	132	71	89.8				
ARA (mg/L)	132	71	172.0				
Iron (mg/L)	8.6	4.0	0.3				
Folate (µg/L)	219	85	24.5				

a. 3- and 6-month average



Longitudinal Patterns of Myelination



Compared with infants fed the control formula, those fed the interventional formula had:


- Significantly increased brain myelin content at 3, 6, 12, and 24 months of age
- Significantly increased rate of myelination throughout the first year of life

MFGM As a Source of Myelin Nutrients

Myelin Sheath

phospholipid glycolipid cholesterol MOG CNP Myelin sheath

MFGM



MFGM As a Source of Myelin Nutrients


BAMBAM Study of Health Neurodevelopment


2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023


Infants who received formula without added bovine MFGM (n = 28)

Infants who received formula with added bovine MFGM (n = 43)

Healthy term infants who received ≥90% formula for the first 3 months of life without a family history of learning or psychiatric disorders (excluding maternal MDD during pregnancy)








Infants who received the formula with added MFGM had:

 Significantly increased brain myelin content over the first 2 years of life throughout motor related regions.

MFGM As a Source of Myelin Nutrients



Infants who received the formula with added MFGM had:

- Significantly increased brain myelin content over the first 2 years of life throughout motor related regions.
- Significantly increased motor skill development.

Key Takeaways

- Nutrients, including folic acid, iron, cholesterol, LC-PUFAs, and sphingomyelin are important for white matter development and brain connectivity
- These nutrients are amply provided in human milk and partially explain observed cognitive differences between breastfed and formula-fed infants
- Formulas with supplemental DHA and sphingomyelin appear to promote improved myelination and brain maturation
- Observational and RCT findings suggest we can improve infant neurodevelopment through improved nutrition, even in a generally healthy child population
- Nutrition is only one of many factors that influence a child's development: love, read, and play with your child!



Helping Little Brains Do Big Things

www.babyimaginglab.com sdeoni@mac.com



BILL&MELINDA
GATES foundation


Nestle Research

Supplemental MFGM & Neurodevelopmental Outcomes


Assessing Cognitive Outcomes

John Colombo, PhD

Specific Cognitive Functions



Developmental Course of Cognitive Functions



Clinical Trial Outcomes to Measure Brain Development


When designing a clinical trial, identifying outcomes to effectively evaluate the treatment is critical.

Options for measuring neurodevelopment include:

- Screening assessments
- Parent report measures (questionnaires)
- Standardized global developmental measures
- Tests of specific cognitive skills


Measuring Executive Function: Modified Stroop Task^{1,2}

- Test: asks children to respond to a stimulus based on a nonintuitive rule
- Cognitive process measured: inhibitory control, rule-learning and strategy, and working memory
- Age group: ≥30 months




Measuring Executive Function: Dimensional Change Card Sort (DCCS) Task¹⁻³

- **Test:** asks children to sort cards into boxes based on a specific characteristic (eg, color) and then asks them to *switch* and sort cards based on a different characteristic (eg, shape) and then again based on a conditional rule
- Cognitive process measured: rule-learning and cognitive flexibility
- Age group: ≥30 months



Measuring Executive Function: Go/No-Go Task


- **Test:** asks children to perform a quick motor response when specific stimuli are displayed (ie, "go" stimuli) and withhold this response for other stimuli (ie, "no-go" stimuli or distractors); often used in conjunction with event-related brain potential (ERP) recording¹
- Measures: inhibitory control¹
- Age group: usually ≥60 months, but has been used in younger children with some success²



Supplemental MFGM & Neurodevelopmental Outcomes

Effects of MFGM Supplementation

Swedish MFGM Study: Neurodevelopment at 12 Months



- Randomized, controlled study
- 160 healthy formula-fed infants were randomized to receive:
 - Standard formula until 6 months of age (n = 68)
 - Standard formula supplemented with MFGM (4% wt:wt) until 6 months of age (n = 73)
- A breastfed reference group was also recruited from the same hospital (n = 72)

Studying the Benefits of MFGM Supplementation in Infant Formula: the Lighthouse MFGM Clinical Trial

- Study design
 - Prospective double-blind randomized controlled trial (RCT)
 - Enrolled 451 infants who were randomized to 12 months of feeding with:
 - » Standard cow's milk-based formula (control)
 - » Standard cow's milk-based formula with added bovine MFGM (5 g/L) and lactoferrin (0.6 g/L) (MFGM+LF) (intervention)
- **Primary outcome:** difference in Bayley Scales of Infant Development, 3rd edition (Bayley-III) cognitive composite scores at 12 months
- Secondary outcomes: tolerability/safety, growth/anthropometrics, and other measures of development




The Lighthouse MFGM Clinical Trial: Ages and Stages Questionnaire Outcomes

ASQ Domain Scores (Repeated Measures Analysis), Mean ± SE

Domains	Day 120		Day 180		Day 275		P value
	Control (n = 187)	MFGM + LF (n = 187)	Control (n = 185)	MFGM + LF (n = 183)	Control (n = 167)	MFGM + LF (n = 166)	for study group
Communication	49.1 ± 0.5	51.4 ± 0.5	50.8 ± 0.5	51.5 ± 0.5	51.5 ± 0.6	52.5 ± 0.6	.010
Gross motor	49.7 ± 0.6	52.3 ± 0.6	48.6 ± 0.6	49.5 ± 0.6	46.2 ± 0.7	47.1 ± 0.7	.010
Fine motor	46.6 ± 0.6	49.5 ± 0.6	52.0 ± 0.6	52.9 ± 0.6	53.4 ± 0.6	54.6 ± 0.6	.002
Problem solving	49.7 ± 0.6	52.1 ± 0.6	49.5 ± 0.6	51.1 ± 0.6	51.9 ± 0.6	52.7 ± 0.6	.003
Personal/social	46.5 ± 0.6	50.2 ± 0.6	47.1 ± 0.6	48.4 ± 0.6	50.0 ± 0.6	51.0 ± 0.6	<.001


The Lighthouse MFGM Clinical Trial: Bayley-III Outcomes at 12 Months








The Lighthouse MFGM Clinical Trial: Bayley-III Outcomes at 18 Months





*P <.001



The Lighthouse MFGM Clinical Trial: Long-Term Follow-Up

Follow-up study design


- Enrolled trial participants who completed 12 months of the assigned study feeding who were 5.5 years (±2 months) at the time of follow-up testing
- 116 of 292 participants meeting eligibility criteria were enrolled
 - » No differences in demographic characteristics between those who did or did not participate in the follow-up study

Primary outcome measures


- WPPSI-IV Full-Scale IQ (a measure of overall intellectual ability)
- 5 primary WPPSI-IV indices (measures of the domain-specific abilities of verbal comprehension, visual spatial, fluid reasoning, working memory, and processing speed)




The Lighthouse MFGM Clinical Trial Long-Term Follow-Up: Outcomes at 5.5 Years





The Lighthouse MFGM Clinical Trial Long-Term Follow-Up: Stroop Task at 5.5 Years





The Lighthouse MFGM Clinical Trial Long-Term Follow-Up: DCCS Task at 5.5 Years





Note: There were no between-group differences in the DCCS task 1 (simple rule) or task 2 (switch rule) scores.

Studying the Benefits of MFGM Supplementation in Infant Formula: the COGNIS Clinical Trial

- Study design
 - Prospective double-blind randomized controlled trial (RCT)
 - Enrolled 170 infants who were randomized to 18 months of feeding with:
 - » Standard cow's milk-based formula (control)
 - » Standard cow's milk-based formula with added functional compounds, including MFGM, synbiotics, and LC-PUFAs (intervention)
- Primary outcome: difference in neurocognitive development measured by Bayley-III scores and other assessments at 4 and 6 years
- Secondary outcomes: tolerability/safety, growth/anthropometrics, infections, and other measures of development



COGNIS Clinical Trial: Neurocognitive Outcomes at 6 Years of Age

K-BIT domain	Standard formula (n = 37)	Intervention formula (n = 39)	Breastfed reference (n = 32)	Adjusted P value (standard vs interventional formula)
Vocabulary	107.91 ± 13.44	113.16 ± 13.31	103.73 ± 14.26	.022
Matrices	111.51 ± 12.07	113.21 ± 12.00	111.78 ± 11.07	.113
IQ	109.64 ± 11.67	113.46 ± 11.50	105.54 ± 12.40	.031

Key Takeaways

- In randomized trials, MFGM supplementation in infant formula has been associated with improved short- and long-term cognitive outcomes, including:
 - Language
 - |Q
 - Executive function
- The effects of early nutrition persist well beyond the period of feeding and into early childhood
 - These nutrients may play a role in the programming of brain structure and function in infancy and early childhood

Questions?

The Early Nutrition Journey and MFGM: Evidence for Improving Cognitive Outcomes

Questions

Please submit your questions using the question cards found on your table





